(MENAFN- GetNews)
"The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccines market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies."Vaccines Market in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0% from 2024 to 2029 according to a new report by MarketsandMarketsTM.
Vaccines Market
in terms of revenue was estimated to be worth
$78.0 billion
in 2024 and is poised to reach
$94.9 billion
by 2029, growing at a CAGR of 4.0% from 2024 to 2029 according to a new report by MarketsandMarkets. Similarly, the vaccines market (excluding COVID-19 vaccines) is projected to reach
USD 80.3 Billion
by 2029 from
USD 53.0 Billion
in 2024, at a CAGR of 8.7% during the forecast period. The growth in the vaccines market is fueled by various factors such as launch of RSV vaccines, rise in adoption of HPV vaccine and strategic partnerships between key market players.
Download an Illustrative overview:
The conjugate vaccine segment is expected to have the dominant share of the vaccine market (excluding COVID-19 vaccines) in 2023.
Based on technology, the global vaccines market (excluding COVID-19 vaccines) is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines, toxoid vaccines, inactivated & subunit vaccines, and other vaccine technologies. In 2023, conjugate vaccine segment dominated the vaccine market. Robust research and development investments, strategic partnerships, and favorable regulatory environments have further bolstered the prominence of conjugated vaccines.
The HPV segment is expected to account for the largest share of the disease indication segment in the vaccines market (excluding COVID-19 vaccines) in 2023.
Based on disease indication, the vaccines market (excluding COVID-19 vaccines) is segmented into, influenza, combination vaccines, pneumococcal disease, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV and other disease indications. RSV vaccine segment is likely to grow at faster CAGR during the forecast period of 2024-2029. Robust investments from pharmaceutical companies, government agencies, and non-profit organizations fuel RSV vaccine development. Additionally, launch of RSV vaccines is likely to uplift the growth of the segment. For instance, in
May 2023, FDA approved ABRYSVO for the prevention of LRTD caused by RSV in individuals 60 years of age or older.
The
Asia Pacific
region (excluding COVID-19 vaccines) is anticipated to grow at significant CAGR during the forecast period.
The
Asia Pacific
(excluding COVID-19 vaccines) is accounted to be the fastest-growing segment of the market. Rapid population growth and urbanization, particularly in countries like
China
and
India, are driving increased demand for vaccines to combat infectious diseases. Additionally, rising healthcare expenditure and government initiatives aimed at improving vaccination coverage further stimulate market growth. Additionally, the growing prevalence of
infectious diseases
coupled with increasing awareness about preventive healthcare measures is driving vaccine uptake in the region.
Request Sample Pages:
Vaccines Market Dynamics:
Drivers:
Focus on vaccine development and launches
Rising prevalence of infectious diseases
Increasing immunization programs
Advancements in vaccine technology
Government support and funding for vaccine development
Restraints:
High cost of vaccine development
Opportunities:
Rising focus on therapeutic vaccines
Extensive R&D for vaccines and increased investments in clinical trials
Challenge:
Stringent regulatory processes
Product recalls
Key Market Players of
Vaccines Industry :
The vaccines market is consolidated, with a small number of players competing for market share.
GSK plc (UK), Merck & Co., Inc (US) Pfizer Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services, Inc (US), AstraZeneca (UK), Serum Institute Of India Pvt. Ltd (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company Limited (Japan), Panacea Biotec (India), Biological E Limited (India), Bharat Biotech (India) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Supply Side- 80%, and Demand Side - 20% By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25% By Region:
North America
-40%,
Europe
-25%,
Asia-Pacific
-20%,
Latin America
-10%,
Middle East-4% and
Africa
-1%
Get 10% Free Customization on this Report:
MENAFN06052024003238003268ID1108180444
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.